Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: Conditioning regimens with fludarabine

Hematology Journal

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Carella, Angelo Michele ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE   (Italy)

Author keywords

Fludarabine; Hematological malignancies; Nonmyeloablative allogeneic SCT

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; IDARUBICIN; MELPHALAN; PURINE DERIVATIVE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; DONOR; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ERADICATION THERAPY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; RECIPIENT; RELIABILITY; REVIEW; TUMOR CELL;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 2942591030     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200393     Document Type: Review

References (46)

1. McCarthy NJ, Bishop MR. Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. Oncologist 2000; 5: 487-496.
2. Beguin Y, Baron F. Minitransplants: allogeneic stem cell transplantation with reduced toxicity. Acta Clin Belg 2003; 58: 37-45.
3. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
4. Giralt S, Anagnostopoulos A, Shahjahanan M, Champlin R. Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Semin Hematol 2002; 39: 57-62.
5. Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Nonmyeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program) 2001; 375-391.
6. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
7. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: nonmyeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
8. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
9. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
10. Giralt S, Khouri I, Champlin R. Non myeloablative 'mini transplants'. Cancer Treat Res 1999; 101: 97-108.
11. Champlin R. Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies. Hematology (Am Soc Hematol Educ Program) 1999; 413-416.
12. Craddock C. Nonmyeloablative stem cell transplants. Curr Opin Hematol 1999; 6: 383-387.
13. Plunkett W, Sanders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther 1991; 49: 239-268.
14. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
15. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P et al. The expanding role of fludarabine in hematologic malignancies. Leukemia Lymphoma 1994; 14 (Suppl 2): 11-16.
16. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000; 25: 345-350.
17. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
18. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
19. Childs R, Contentin N, Clave E, Bahceci E, Hensel N, Boland C et al. Reduced toxicity and transplant related mortality (TRM) following nonmyeloablative allogeneic peripheral blood stem cell transplantation for malignant diseases. Blood 1999; 94 (Suppl 1): 1743 (abstract).
20. Khouri I, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based non-ablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
21. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747-2753.
22. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
23. Khouri I, Saliba R, Giralt S, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3593-3595.
24. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028.
25. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000; 26: 615-620.
26. Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P et al. Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant 2001; 28: 335-339.
27. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367-373.
28. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924.
29. Giralt S, Gajewski J, Khouri I, Korbling M, Claxton D, Mehra R et al. Induction of graft-vs-leukemia (GVL) as primary treatment of chronic myelogenous leukemia (CML). Blood 1997; 90 (Suppl 1): 1857 (abstract).
30. Slavin S, Nagler A, Naparstek E, Varadi G, Ben-Yosef R, Ackerstein A et al. Allogeneic nonmyeloablative stem cell transplantation (NST) as an emerging new modality for immunotherapy of hematologic malignancies and non-malignant disorders. Blood 1998; 92 (Suppl 1): 2132 (abstract).
31. Dighiero G, Binet JL. Chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38 (Suppl 2): S41-S61.
32. Cheson BD. CHOP plus rituximab - balancing facts and opinion. N Engl J Med 2002; 346: 280-282.
33. Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002; 29 (1 Suppl 2): 36-40.
34. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF et al. Allogeneic bone marrow transplantation for poor prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 1996; 100: 299-307.
35. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan Jr F et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790-794.
36. Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841-848.
37. Imrie KR, Linch DC, Czuczman MS Anticancer Drugs 2002; 13 (Suppl 2): S19-S24.
38. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry Data. J Clin Oncol 1992; 10: 1690-1695.
39. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
40. Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574-2579.
41. Pérez-Simón JA, Martino R, Alegre A, Tomas JF, De Leon A, Caballero D et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after nonmyeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104-108.
42. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
43. Molina A, Sahebi F, Maloney DG, Sandmaier BM, McSweeney P, Kashyap A et al. Nonmyeloablative peripheral blood stem cell allografts following cytoreductive autotransplants for the treatment of multiple myeloma. Blood 2000; 96 (Suppl 1): 480a.
44. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
45. Pérez-Simón JA, Kottaridis D, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
46. Carella AM, Beltrami G, Scalzulli PR, Carella AM Jr., Corsetti MT. Alemtuzumab can successfully treat steroid-refractory graft-versus-host-disease. Bone Marrow Transplantation 2004; 33: 131-132.